Perspectives

The company had established a presence in the oncology cell therapy space with numerous clinical development programs and strategic acquisitions which added platform capabilities. In light of the rapidly-accumulating data suggesting the clinical activity – and possibly curative potential – of CAR-T cell therapy in autoimmune and inflammatory diseases (AIID), the company asked Lumanity to assess the opportunity for its cell therapy technology and delineate why and how the company should pursue the development of cell therapy candidates for AIID applications.